✦ LIBER ✦

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Apremilast, an oral phosphodiesterase 4

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Long-term safety and tolerability of apr

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Improvements in patient-reported outcome

✍ Vibeke Strand, David Fiorentino, ChiaChi Hu… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 457 KB

A phase 2b trial of baricitinib, an oral

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Impact of adalimumab treatment on health

✍ D. Revicki; M.K. Willian; J.-H. Saurat; K.A. Papp; J.-P. Ortonne; C. Sexton; A. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

Impact of ustekinumab on health-related

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB